SAT-679 Fast Score Vs. Fib-4: Identifying At-risk Mash In Type 2diabetes And Masld
Sign Up to like & getrecommendations! Published in 2025 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvaf149.113
Abstract: Abstract Disclosure: S.A. Alnashaba: None. Y. Elamin: None. M. Ismail: None. R. Al Argan: None. Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most prevalent chronic liver disease globally. A subset of patients… read more here.
Keywords: risk mash; mash; advanced fibrosis; fast score ... See more keywords
1326-P: At-Risk MASH Diagnosis in Patients with Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2024 at "Diabetes"
DOI: 10.2337/db24-1326-p
Abstract: Introduction/Objectives: The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes mellitus (T2DM) in US is around 30% and about 20% of patients have liver fibrosis. This study aims to explore the… read more here.
Keywords: diagnosis; risk mash; control; none ... See more keywords
FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis
Sign Up to like & getrecommendations! Published in 2024 at "World Journal of Gastroenterology"
DOI: 10.3748/wjg.v30.i18.2440
Abstract: BACKGROUND Non-alcoholic fatty liver disease (NAFLD) with hepatic histological NAFLD activity score ≥ 4 and fibrosis stage F ≥ 2 is regarded as “at risk” non-alcoholic steatohepatitis (NASH). Based on an international consensus, NAFLD and… read more here.
Keywords: risk mash; aspartate transaminase; risk; high risk ... See more keywords